CN114761003B - 具有雄激素受体降解活性的新型脲类及其用途 - Google Patents
具有雄激素受体降解活性的新型脲类及其用途 Download PDFInfo
- Publication number
- CN114761003B CN114761003B CN202080079154.8A CN202080079154A CN114761003B CN 114761003 B CN114761003 B CN 114761003B CN 202080079154 A CN202080079154 A CN 202080079154A CN 114761003 B CN114761003 B CN 114761003B
- Authority
- CN
- China
- Prior art keywords
- piperidin
- carboxamide
- piperazin
- methyl
- dimethylpiperazine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962903997P | 2019-09-23 | 2019-09-23 | |
| US62/903,997 | 2019-09-23 | ||
| PCT/US2020/051997 WO2021061642A1 (en) | 2019-09-23 | 2020-09-22 | Novel ureas having androgen receptor degradation activity and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114761003A CN114761003A (zh) | 2022-07-15 |
| CN114761003B true CN114761003B (zh) | 2023-12-29 |
Family
ID=74879893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080079154.8A Expired - Fee Related CN114761003B (zh) | 2019-09-23 | 2020-09-22 | 具有雄激素受体降解活性的新型脲类及其用途 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US11420956B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4034114A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022549222A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114761003B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021061642A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3526202T1 (sl) | 2016-10-11 | 2025-04-30 | Arvinas Operations, Inc. | Spojine in postopki za ciljno razgradnjo androgenskih receptorjev |
| WO2020160295A1 (en) | 2019-01-30 | 2020-08-06 | Montelino Therapeutics, Llc | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor |
| EP4034114A4 (en) * | 2019-09-23 | 2023-07-26 | Accutar Biotechnology Inc. | Novel ureas having androgen receptor degradation activity and uses thereof |
| WO2021127443A1 (en) | 2019-12-19 | 2021-06-24 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| CN115996918A (zh) | 2020-05-09 | 2023-04-21 | 阿尔维纳斯运营股份有限公司 | 制造双官能团化合物的方法、双官能团化合物的超纯形式以及包括所述双官能团化合物的剂型 |
| WO2022019597A1 (ko) * | 2020-07-21 | 2022-01-27 | 주식회사 유빅스테라퓨틱스 | 안드로겐 수용체 분해용 화합물 및 이들의 의약 용도 |
| US20240376118A1 (en) * | 2021-09-13 | 2024-11-14 | Montelino Therapeutics, Inc. | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor |
| KR20230112501A (ko) | 2022-01-20 | 2023-07-27 | 주식회사 유빅스테라퓨틱스 | 안드로겐 수용체 분해활성을 갖는 화합물 및 이들의 의약 용도 |
| US12662467B2 (en) | 2022-04-18 | 2026-06-23 | BioThery X, Inc. | Isoindolinones, pharmaceutical compositions, and therapeutic applications |
| US20240190842A1 (en) * | 2022-11-09 | 2024-06-13 | Accutar Biotechnology Inc. | Substituted quinolinone-8-carbonitrile derivatives having androgen degradation activity and uses thereof |
| AU2024392985A1 (en) | 2023-12-08 | 2026-06-04 | Arvinas Operations, Inc. | Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998003502A1 (en) * | 1996-07-24 | 1998-01-29 | Celgene Corporation | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and method of reducing tnf-alpha levels |
| EP3135669A1 (en) * | 2014-04-24 | 2017-03-01 | Dong-A ST Co., Ltd. | Oxazolidine-based compound and selective androgen receptor agonist comprising same |
| CN108048567A (zh) * | 2012-07-27 | 2018-05-18 | 阿拉贡药品公司 | 用于确定抵抗雄激素受体疗法的方法和组合物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000017163A1 (en) | 1998-09-22 | 2000-03-30 | Yamanouchi Pharmaceutical Co., Ltd. | Cyanophenyl derivatives |
| US7629360B2 (en) * | 1999-05-07 | 2009-12-08 | Celgene Corporation | Methods for the treatment of cachexia and graft v. host disease |
| ES2393333T3 (es) * | 2002-07-12 | 2012-12-20 | Astellas Pharma Inc. | Derivado de N-fenil-(2R,5S)dimetilpiperazina |
| WO2005011011A1 (en) * | 2003-07-21 | 2005-02-03 | Unaxis Usa Inc. | Etching method for making chalcogenide memory elements |
| US20050124625A1 (en) * | 2003-10-21 | 2005-06-09 | Salvati Mark E. | Piperazine derivatives and their use as modulators of nuclear hormone receptor function |
| US20130197009A1 (en) * | 2010-10-22 | 2013-08-01 | Astellas Pharma Inc. | Antagonist for mutant androgen receptor |
| EP4649963A3 (en) | 2014-04-14 | 2026-05-13 | Arvinas Operations, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| US20180228907A1 (en) * | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| SI3526202T1 (sl) * | 2016-10-11 | 2025-04-30 | Arvinas Operations, Inc. | Spojine in postopki za ciljno razgradnjo androgenskih receptorjev |
| IL325835A (en) * | 2016-12-23 | 2026-03-01 | Univ Yale | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides |
| EP4034114A4 (en) * | 2019-09-23 | 2023-07-26 | Accutar Biotechnology Inc. | Novel ureas having androgen receptor degradation activity and uses thereof |
-
2020
- 2020-09-22 EP EP20868648.5A patent/EP4034114A4/en active Pending
- 2020-09-22 CN CN202080079154.8A patent/CN114761003B/zh not_active Expired - Fee Related
- 2020-09-22 WO PCT/US2020/051997 patent/WO2021061642A1/en not_active Ceased
- 2020-09-22 JP JP2022517875A patent/JP2022549222A/ja active Pending
- 2020-09-22 US US17/028,612 patent/US11420956B2/en active Active
-
2021
- 2021-05-26 US US17/331,015 patent/US11220490B2/en not_active Expired - Fee Related
-
2022
- 2022-06-27 US US17/850,289 patent/US20230150973A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998003502A1 (en) * | 1996-07-24 | 1998-01-29 | Celgene Corporation | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and method of reducing tnf-alpha levels |
| CN108048567A (zh) * | 2012-07-27 | 2018-05-18 | 阿拉贡药品公司 | 用于确定抵抗雄激素受体疗法的方法和组合物 |
| EP3135669A1 (en) * | 2014-04-24 | 2017-03-01 | Dong-A ST Co., Ltd. | Oxazolidine-based compound and selective androgen receptor agonist comprising same |
Non-Patent Citations (1)
| Title |
|---|
| 雄激素非依赖性前列腺癌细胞雄激素受体靶向降解的实验研究;施云峰等;《中华男科学杂志》;20091220;第15卷(第12期);第1059-1063页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US11420956B2 (en) | 2022-08-23 |
| US20230150973A1 (en) | 2023-05-18 |
| CN114761003A (zh) | 2022-07-15 |
| US20210087170A1 (en) | 2021-03-25 |
| JP2022549222A (ja) | 2022-11-24 |
| US11220490B2 (en) | 2022-01-11 |
| EP4034114A4 (en) | 2023-07-26 |
| WO2021061642A1 (en) | 2021-04-01 |
| EP4034114A1 (en) | 2022-08-03 |
| US20210300901A1 (en) | 2021-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7307796B2 (ja) | アンドロゲン受容体分解活性を有する新規の置換キノリン-8-カルボニトリル誘導体およびその使用 | |
| US11220490B2 (en) | Ureas having androgen receptor degradation activity and uses thereof | |
| CN113164409B (zh) | 具有雌激素受体α降解活性的化合物及其用途 | |
| EP4420728A2 (en) | Novel chroman derivatives having estrogen receptor degradation activity and uses thereof | |
| WO2021061644A1 (en) | Novel substituted quinoline-8-carbonitrile derivatives with androgen receptor degradation activity and uses thereof | |
| US12234218B2 (en) | Heterocyclic compounds as modulators of mGluR7 | |
| EP3569592B1 (en) | Hdac6 selective inhibitors, preparation method therefor, and application thereof | |
| JP2024527577A (ja) | 3,4-メチレンジオキシメタンフェタミン及び関連する幻覚剤ならびにその使用 | |
| WO2024102784A1 (en) | Substituted quinolinone-8-carbonitrile derivatives having androgen degradation activity and uses thereof | |
| WO2023125182A1 (zh) | 一种丙酸衍生物及其在医药上的应用 | |
| KR102547709B1 (ko) | 아제티딘 유도체 | |
| WO2022063297A1 (zh) | 喹唑啉衍生物及其制备方法和用途 | |
| KR20260054707A (ko) | Cdk4 키나아제 억제제로 사용되는 화합물 및 이의 응용 | |
| HK40041475B (en) | Substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof | |
| HK40041475A (en) | Substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof | |
| HK40115205A (en) | Novel chroman derivatives having estrogen receptor degradation activity and uses thereof | |
| IL319492A (en) | A carbonyl-fused heterocyclic derivative that acts as a ubiquitin-specific protease | |
| HK40001081A (en) | Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20231229 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |